Vir’s VIR-2482 Flunks In Phase II As Company Shifts Focus To Other Programs

 
• By Alaric DeArment
  
Vir said its trial of VIR-2482 in influenza A prevention was unsuccessful • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D